Houston, TX -- (SBWIRE) -- 02/11/2013 -- AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Cereplast Inc (PINK:CERP) fell 17.04% and is trading at $0.0375. Cereplast, Inc. (Cereplast) is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line), which replaces up to 90% of the petroleum-based content of traditional plastics with materials from renewable resources.
Can CERP Rebound After The Recent Slump and Investors Can Make Money? Find Out Here
A.P. Pharma, Inc. (OTC:APPA) is lower 1.07% and is trading at $0.738. A.P. Pharma, Inc. operates as pharmaceutical company focused on the development and commercialization of medical treatments utilizing its Biochronomer, a polymer-based drug delivery technology. The Company's focus is on its lead product candidate, APF530, which aims to prevent chemotherapy-induced nausea and vomiting (CINV).
How Should Investors Trade APPA After The Recent Volatile Moves? Find Out Here
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) is higher 3.54% and is trading at $5.32. Rosetta Genomics Ltd., is seeking to develop and commercialize diagnostic tests based on discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology.
Is ROSG Showing Any Sign of Buy At The Current Market Price? Get Our Free Trend Analysis Here
Tranzyme Inc (NASDAQ:TZYM) added 1.65% and is trading at $0.610. Tranzyme, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. The Company is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders.
Can TZYM Rebound After The Recent Slump and Investors Can Make Money? Find Out Here
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
Winning Media LLC
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)